Clinical Trials
5
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
Phase 1
Recruiting
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: ASC50 tablets or matching placebo
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Ascletis Pharma (China) Co., Limited
- Target Recruit Count
- 94
- Registration Number
- NCT07024602
- Locations
- 🇺🇸
Ascletis Clinical Site, Miami, Florida, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
Phase 2
Recruiting
- Conditions
- Chronic Weight Management
- Interventions
- Drug: ASC30 tablets or ASC30 tablets A1 or placebo
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Ascletis Pharma (China) Co., Limited
- Target Recruit Count
- 125
- Registration Number
- NCT07002905
- Locations
- 🇺🇸
Ascletis Clinical Site, San Antonio, Texas, United States
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
Phase 1
Recruiting
- Conditions
- Chronic Weight Management
- Interventions
- Drug: ASC47 +SemaglutideDrug: Placebo+Semaglutide
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Ascletis Pharma (China) Co., Limited
- Target Recruit Count
- 24
- Registration Number
- NCT06972992
- Locations
- 🇺🇸
Ascletis Clinical Site, San Antonio, Texas, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Ascletis Pharma (China) Co., Limited
- Target Recruit Count
- 72
- Registration Number
- NCT06680440
- Locations
- 🇺🇸
Ascletis clinical site, Salt Lake City, Utah, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
Phase 1
Recruiting
- Conditions
- Chronic Weight Management
- Interventions
- Drug: ASC30 Injection, for subcutaneous use or placebo
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Ascletis Pharma (China) Co., Limited
- Target Recruit Count
- 115
- Registration Number
- NCT06679959
- Locations
- 🇺🇸
Ascletis clinical site, San Antonio, Texas, United States
News
No news found